IntoCell

IntoCell ROIC

The Return on Invested Capital (ROIC) of IntoCell (287840.KQ) as of Oct 27, 2026 is -30.51 %. In the previous year, Return on Invested Capital (ROIC) was -56.39 % — a change of -45.88% (higher).

ROIC

-30.51 %

YoY

-45.88%

Last updated:

Return on Invested Capital (ROIC) of IntoCell is 2025 -30.51 % . Return on Invested Capital (ROIC) of IntoCell was 2024 -56.39 % . It decreases by -45.88% higher compared to the previous year.

The IntoCell ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2022
-29.00 KRW
Jan 1, 2023
-72.17 KRW
Jan 1, 2024
-56.39 KRW
Jan 1, 2025
-30.51 KRW
The IntoCell ROIC history
YEARROICYoY
-30.51 %-45.88%
-56.39 %-21.87%
-72.17 %+148.85%
-29.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IntoCell Stock analysis

What does IntoCell do? IntoCell, Inc. generates revenue through the development and licensing of its ADC platform technologies, including the OHPAS linker technology and PMT platform technology. The company focuses on creating proprietary drug technologies for ADC development, targeting pharmaceutical companies seeking to improve drug delivery systems. Its primary customers are pharmaceutical firms interested in enhancing the efficacy and safety of antibody-drug conjugates through advanced linker and payload modification solutions. The OHPAS platform technology serves as a critical linker connecting drugs to antibodies, while the PMT platform technology reduces drug uptake into normal cells, addressing key challenges in ADC development. IntoCell's proprietary drug technology complements these platforms, offering specialized solutions for ADC manufacturers. The company's R&D-driven approach positions it as a provider of innovative tools for the biopharmaceutical industry. IntoCell's business model centers on technology licensing and development contracts with pharmaceutical partners. By leveraging its expertise in linker and payload modification, the company aims to secure long-term partnerships that drive revenue through milestone payments and royalties on commercialized products. The firm's focus on proprietary technologies ensures a competitive edge in the ADC market. IntoCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IntoCell stock

Return on Invested Capital (ROIC) of IntoCell is -30.51 % in 2025.

Return on Invested Capital (ROIC) of IntoCell changed from -56.39 % to -30.51 %, representing a -45.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) IntoCell since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s IntoCell with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — IntoCell

All Key Metrics — IntoCell